Kornimate/medical-research-clean huggingface dataset:
effectiveness of d-cycloserine as an aid to enhance learning for individuals with ocd receiving behavior therapy

Conditions: Obsessive-Compulsive Disorder

Summary: this study will assess the effectiveness of seromycin (d-cycloserine) in enhancing the positive effects of behavior therapy for people with obsessive-compulsive disorder (ocd).

we hope to enroll 50 subjects in a double-blind, placebo-controlled study of d-cycloserine augmentation of behavior therapy for obsessive-compulsive disorder. all subjects will undergo a pre-treatment assessment, and then be randomly assigned to receive seromycin (100 mg) or placebo one-hour before each of 10 therapy sessions. subjects will then come in for a treatment planning session and the behavior therapy sessions delivered twice weekly for 5 weeks. comprehensive assessments of obsessive-compulsive symptoms, mood state, and cognitions will be given at baseline, after 5 treatment sessions, after 10 sessions and 1 month and 6 months post-treatment.

Eligibility criteria:
inclusion criteria: * structured clinical interview for dsm-iv (scid) diagnosis of obsessive compulsive disorder * score of greater than 16 on the yale-brown obsessive compulsive scale * negative urinary beta-human chorionic gonadotropin (hcg) test exclusion criteria: * currently taking or have taken an unstable dose of psychotropic medications within 2 months prior to enrollment * currently taking medications that may interfere with the study medication * history of seizure disorder or other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory, endocrine, neurologic, or blood-related disease) * current diagnosis of tuberculosis * other psychiatric diagnoses (e.g., alcohol dependence, bipolar disorder, psychosis, organic mental disorder, or development disorder) that are of greater concern than the obsessive-compulsive disorder diagnosis * currently taking medications that may lower seizure threshold (e.g., including clozapine, pethidine, and the following antibiotics in high dosage: penicillins, cephalosporins, amphotericin, and imipenem) * poses a serious suicidal or homicidal threat * currently undergoing psychotherapy * failure to benefit from ten or more sessions of previous exposure and response prevention (erp) treatment * pregnant or breastfeeding

Keywords: ocd
mri findings of epiphyseal growth plate in healthy children

Conditions: OCD - Osteochondritis Dissecans

Summary: the purpose of the study is to determine if by using mri changes can be identified changes early on in the knees of young children that may be at risk for developing osteochondritis dissecans. if mri can identify changes then better council can be offered about the risks of future activity and treatment options.

each subject will be asked to undergo an mri at enrollment, six,12, and 18 months. subjects will be monitored for evidence of osteochondritis dissecans in order to determine if we can identify it and then create a treatment program to allow these children to avoid developing definitive disease

Eligibility criteria:
inclusion criteria: 6-10-year-old children with a sibling with known ocd and 6-10-year-old children with a known ocd in the contralateral knee exclusion criteria: unable to undergo an mri
low-dose tolvaptan for inpatient hyponatraemia.

Conditions: Hyponatremia; SIADH

Summary: this is a retrospective cohort study to assess the safety and efficacy of low first dose of tolvaptan and low or standard second dose of tolvaptan in patients with moderate to severe hyponatraemia associated with siadh not responding to conservative means of hyponatraemia management. patients are treated as part of standard clinical care. there is growing evidence that treating patients with saidh induced hyponatraemia using a low dose of tolvaptan with 7.5mg (below licensed lowest 15mg daily dose). this is the largest study to date and seeks to validate the efficacy and safety or this lower than approved dose of tolvaptan in patietns who only need a first dose but also in patients who need a second low or srandard dose of tolvaptan.


Eligibility criteria:
inclusion criteria: * all patients presenting to accident \& emergency department or seen as inpatients with moderate to severe hyponatraemia (sna: \<125mmol) associated with siadh and not responding to conservative measures of hyponatraemia management. * patients of all genders aged 18-90 y.o exclusion criteria: * pregnant women and patients aged \< 18y.o * hyponatraemia not associated with siadh

Keywords: tolvaptan
cartography of allodynic and hypoasthetic territories following tka

Conditions: Pain, Postoperative; Neuropathic Pain

Summary: the purpose of this study is to realize a cartography of the allodynic and hypoasthetic territories associated with a neuropathic pain appearing in patients who underwent a total knee arthroplasty (tka)

the occurrence of post-surgical pain depends on the surgical procedure performed, the surgical site and patients-dependents characteristics. post surgical pain became chronic when it persist beyond two month. chronic post-surgical pain (cpsp) is one of the most common complications after surgery. nerve injury during surgery has been implicated in the development of cpsp. some patients with cpsp have neuropathic pain (np). np is pain cause by damage or disease affecting the somatosensory nervous system. it may be associated with abnormal cutaneous sensation such as hypoesthesia (partial loss of sensitivity to sensory stimuli) or allodynia (pain from normally non-painful stimuli) total knee arthroplasty (tka) present a high risk of injury of the infrapatellar branch of the saphenous nerve, thus can cause the appearance of neuropathic post-surgical pain. only few data are available concerning the skin areas affected after this surgery. the goal of this study is to analyse the localization of allodynic or hypoasthetic territories that may appear after tka. the investigators will include 200 patients undergoing tka surgery at the chu-amiens-picardie. patient will be seen the day before their surgery, and at follow-up visits at 6 weeks, 6 months and one year postoperatively. a dn diagnostic test (dn4 test) will be performed at each visits. the cartography will be performed on each dn4-positive patients. in addition, patients will also complete questionnaires to assess the intensity of pain, quality of life and level of anxiety. thus, the knowledge of the localization of allodynic or hypoasthetic territories will allow a most efficient an faster detection and relief of post-surgical neuropathic pain.

Eligibility criteria:
inclusion criteria: * major patient benefit from a first setting operation of tka (total knee arthroplasty) by standard medial arthrotomy * patient signed an informed consent * patients receiving social coverage exclusion criteria: * patient not wishing to be part of the study, or unable to consent, * patient under guardianship or deprived of his liberty * patients with neuropathic pain in the territory concerned preoperatively * patient who underwent tka laying by a technique other than standard medial arthrotomy
the use of dual chamber icd with special programmed features to lower the risk of inappropriate shock

Conditions: Ventricular Tachycardia; Ventricular Fibrillation; Atrial Fibrillation; Supraventricular Tachycardia

Summary: the rapture study will determine whether dual chamber defibrillators with atrial prevention and termination therapies, minimized ventricular pacing, and remote monitoring will reduce the rate of inappropriate shocks and improve quality of life compared to optimally programmed back-up pacing only single chamber icds when used for primary prevention of sudden cardiac death

while implantable cardioverter-defibrillator (icd) therapy has become the gold standard for sudden death prevention in high risk individuals, reduction of device associated morbidity remains a significant problem. rapidly conducted atrial tachyarrhythmias inappropriately detected as ventricular tachycardia (vt) are the most common cause for inappropriate shocks in icd recipients, affecting 10 to 40% of patients. large multicenter trials have shown modest benefits of atrial pacing in preventing atrial fibrillation, however right ventricular (rv) pacing was not limited, thus any favorable effects associated with atrial prevention and treatment may have been offset by the rv pacing. new algorithms to prevent rv pacing are now made available in our current devices. the choice of dual chamber versus single chamber icd for primary prevention warrants re-assessment of atrial prevention and termination therapies, without the potentially adverse effects of rv pacing. this multi center pilot study will enroll 100 eligible subjects, 50 to single chamber and 50 to dual chamber icds. patients will be followed for one year.

Eligibility criteria:
inclusion criteria: * candidates for icd for primary prevention according to american heart association/american college of cardiology (aha/acc) guidelines who have a clinical indication for icd implantation for ventricular arrhythmia or sudden death prevention. * the ability to understand the scope of the study, provide written informed consent, and a willingness to complete all study visits and associated procedures. exclusion criteria: * pregnant women * age \<18 years old * inability to provide consent * on a heart transplant waiting list * life expectancy \<1 year * indication for pacing * atrioventricular (av) node ablation * permanent atrial fibrillation or atrial flutter * indication for cardiac resynchronization * preexisting, separate pacemaker pulse generator that won't be explanted * intra-aortic balloon pump or other device * inotropic drug (not digitalis) necessary for hemodynamic support * chronic serious bacterial infection * inability to receive pectoral non-thoracotomy lead icd * inability to program device according to protocol * history of out of hospital cardiac arrest (ohca) or sustained ventricular tachycardia as an indication for icd (secondary prevention indication)

Keywords: shock prevention single vs. dual chamber reduce ventricular pacing atrial fibrillation remote monitoring icd implantable cardioverter defibrillator
toleromune grass exposure unit study

Conditions: Grass Allergy; Rhinoconjunctivitis

Summary: grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. toleromune grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy. this study will look at the efficacy, safety and tolerability of three doses of toleromune grass in grass allergic subjects following challenge with with grass in an environmental exposure unit (eeu).

this study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of toleromune grass in grass allergic subjects with allergic rhinoconjunctivitis. the efficacy of toleromune grass will be explored in subjects using an eeu (environmental exposure unit). the study will consist of 3 study periods. in period 1, screening will be performed up to a maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic, at the investigator's discretion. baseline challenge will consist of 4 visits to the eeu at least 3 days before randomisation. in period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of four groups and will receive treatment every 2 weeks (±2 days) for 14 weeks. in period 3, post treatment challenge will consist of 4 visits to the eeu about 25 weeks after the first administration in the treatment period and assessments will be performed identical to those at the baseline challenge. follow-up will be conducted 3-10 days after ptc.

Eligibility criteria:
inclusion criteria * male or female, aged 18-65 years. * minimum 2-year documented history of rhinoconjunctivitis on exposure to grass. * positive skin prick test to grass allergen. * minimum qualifying rhinoconjunctivitis symptom scores exclusion criteria * history of asthma. * a history of anaphylaxis to grassallergen. * subjects with an fev1 \<80% of predicted. * subjects who cannot tolerate baseline challenge in the eeu. * subjects for whom administration of epinephrine is contra-indicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension). * a history of severe drug allergy, severe angioedema or anaphylactic reaction to food. * a history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment).

Keywords: grass allergy rhinoconjunctivitis environmental exposure unit immunotherapy toleromune grass
efficacy of corifollitropin alfa in obese women in terms of clinical and molecular parameters of ivf success

Conditions: Obesity

Summary: the aim of the present study is to determine, whether clinical efficacy of 150 mcg of corifollitropin alfa is the same in normal weighing and obese women. furthermore, investigators want to determine whether oocytes retrieved from normal weighing and obese women, after coh using 150 mcg of corifollitropin alfa, are of same quality on the molecular level.

the dosage of corifollitropin alfa used for controlled ovarian hyperstimulation (coh) is adjusted according to the patient's body weight. meaning, in women with a body weight ≤ 60 kg, a single dose of 100 mcg of corifollitropin alfa is administered for coh and in women with a body weight \> 60 kg, a single dose of 150 micrograms of corifollitropin alfa is administered for coh. these two protocols are comparable in safety and efficacy of follicular stimulation. on the other hand, knowledge about the clinical efficacy of 150 mcg of corifollitropin alfa in obese women (bmi\>30 kg/m2) is lacking. cumulus cells (cc) surround the oocyte and bi-directional communication between oocyte and cc is necessary for the development of mature and quality oocytes. it has been proposed, that analysis of genes, expressed in cc, can serve as an objective indicator of the oocyte's maturity and developmental potential. expression of genes in cc as hyaluronan synthase 2 (has2), follicle-stimulating hormone receptor (fshr), versican (vcan), progesterone receptor (pr), vascular endothelial growth factor c (vegfc), serine protease inhibitor e2 (serpine2), glutathione peroxidase (gpx3), pentraxin 3(ptx3) was reported to correlate with oocyte maturity and developmental potential. the effect of corifollitropin alfa on expression of these genes however, is unknown.

Eligibility criteria:
inclusion criteria: * bmi \> 30 kg/m2 * bmi 18.5-24.9 kg/m2 exclusion criteria: * polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years
a cross-sectional survey to evaluate diabetes management, control, complications, psychosocial aspects of patients with type 2 diabetes in bangladesh

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in asia. the aim of this non-interventional study is to evaluate the the current status of diabetes management, control, and complications in diabetic subjects with type 2 diabetes in bangladesh.


Eligibility criteria:
inclusion criteria: * people with type 2 diabetes mellitus (dm) who are being treated, with any of the non-pharmacological or pharmacological options, at a particular centre for at least 1 year and who have visited the centre within the last 3-6 months * patients willing to sign informed consent form exclusion criteria: * previous participation in this study * unable to comply with protocol requirements * confirmed or suspected pregnancy
translation of the international consensus definition of lars into a bowl dysfunction severity scoring tool (new lars score)

Conditions: Low Anterior Resection Syndrome

Summary: the purpose of this study is to develop a new severity scoring tool for low anterior resection syndrome (lars) drawing on the international consensus criteria for lars as well as opinions of patients with lived-experience of lars.

six out of ten patients have significant bowel problems in the first 12 months after surgery to remove their rectum (last bit of bowel), with as many as 4 out of 10 having longer term issues. this is an operation which is most commonly performed to treat bowel cancer. bowel problems can include having to rush to the toilet, having accidents or leakage into the underwear or difficulty fully emptying the bowels. this condition is called low anterior resection syndrome, or 'lars' for short. the definition of low anterior resection syndrome was developed in 2020 with patient involvement throughout the process so it accurately captures the real-world experience of lars. this definition is to be used to create a new scoring system to measure the severity of lars. the aim of this study is to transform this new definition into a scoring tool which can be used to assess the severity of low anterior resection syndrome and investigate how well various treatments work for lars. it is vital to have patients involved throughout this work to ensure that the new score gives an accurate picture of the severity of these symptoms.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * able and willing to provide informed consent * undergone an anterior resection for cancer, with current bowel continuity exclusion criteria: * currently undergoing adjuvant therapy * recurrent or metastatic disease * unable to participate to complete study procedures (due to intellectual or cognitive impairment; due to insufficient english-language skills (oral and written))

Keywords: qualitative research patient-reported outcome measures colorectal cancer bowel dysfunction
sleep disordered breathing and impaired glucose homeostasis in obese children

Conditions: SDB; T2DM; Obesity

Summary: sdb has been identified as an important risk factor for insulin resistance and the metabolic syndrome. in a recent study in patients with sdb and t2dm it was shown that cpap therapy can lead to improvements in postprandial glucose levels and in glycosylated hemoglobin levels (hba1c). in children, there are only 3 studies that have examined the relations between sdb, obesity and the metabolic syndrome. in order to further understand the relative contribution of sdb to the development of impaired glucose homeostasis and metabolic abnormalities we aim to investigate the prevalence and severity of sdb in children with t2dm compared to obese children without t2dm. the investigators hypothesize that sdb will be more prevalent and more severe among obese children with t2dm compared with the general obese pediatric population.


Eligibility criteria:
inclusion criteria: * diagnosed with t2dm * obese exclusion criteria: -
community resilience to acute malnutrition

Conditions: Malnutrition, Child

Summary: the study evaluates the impact of a multi-sectoral intervention (water, sanitation, and hygiene; training on climate smart activities; care groups for mothers; market gardens) on the prevalence of acute malnutrition as the primary outcome using a randomized intervention trial between 2012-2017 with four points of data collection (2012, 2014, 2015, and 2017).

concern worldwide has developed a model of intervention called community resilience to acute malnutrition (cram). this model is based on the need for (a) the introduction of longer-term programming to build community resilience to shocks, while recognising that there may be a need for humanitarian intervention, and (b) a multi-sectoral package of activities given experience in programming from other settings. the goal of the study is to rigorously test the impact of the model and associated activities on community resilience to shocks in the goz beida area of chad. where community resilience is proxied by the primary outcome variable: acute malnutrition. in order to answer this question, 69 villages had been randomized to either receive the full multi-sectoral program or not. in each village, approximately 20 households were surveyed (randomly selected from a household list from a previous emergency distribution) for a total of 1420 households. those households were then surveyed in november/december 2012 (prior to the intervention), and again a the same time period in 2014, 2015, and 2017. data was collected on household demographics, livelihoods, child health, and nutrition, including child (6-59 months) anthropometry.

Eligibility criteria:
inclusion criteria: * child is from household with b, c, or d wealth ranking (wealth ranking is from a-d with a being the highest wealth and d being the lowest wealth) * child is between the ages of 6-59 months * child is present in the selected household at the time of the survey exclusion criteria: * child has a skin disorder * too ill to be measured on height board or weight scale
antimicrobial coated sutures in paediatric surgery

Conditions: Wound Infections

Summary: the purpose of this study is to determine if suture material coated by antimicrobial agent triclosan would decrease the incidence of surgical site infections (ssis) in paediatric surgery compared to ordinary sutures. 1500 children (age form 4 weeks to 18 years) coming for general pediatric surgery to the oulu university hospital are randomised to have sutures coated with triclosan (vicryl plus, monocryl plus) or ordinary sutures. the occurrence of ssis is monitored by email questionnaires to the parents on days 10 and 30. the diagnosis of ssis are made along cdc criteria.

we have now (spring 2014) recruited almost 1500 patients to the study. when reviewing the recruited material, we found out that the study suture material has been used in 83% of the recruited patients. the reasons for this have been clinical issue during the operation where melting suture material may not have been needed at all. we have decided to prolong recruiting so that we would gather the calculated sample size of 1500 of patient with study suture material. this will take 12-18 months (probably till autumn 2015).

Eligibility criteria:
inclusion criteria: * any general surgery during childhood where melting sutures will be used exclusion criteria: * wound infection as a cause for surgery